Scientific News
The findings of a new study suggest that the interplay between diet, microbiota and intestinal immunity regulates obesity, diabetes and other metabolic conditions.
A gut microbial metabolite called trimethylamine N-oxide, or TMAO, could improve immunotherapy success in pancreatic cancer.
The findings of a new research suggest that microbiota-based therapies can help improve clinical outcomes after organ transplants.
Researchers have developed a new technique that can identify which gut microbes have migrated from the gut to the blood.
A recent study shows that some bacterial strains are similar to the human host phylogeny, suggesting that they evolved alongside humans.
The findings of a new study suggest that Bacteroides can metabolize cholesterol, thus helping to regulate its levels in the blood.
Together with Prof. Ted Dinan (UCC Ireland), in this episode we discuss the link between gut, insomnia and anxiety.
Sam Costello (The Queen Elizabeth Hospital in Adelaide) presented recent evidences about FMT and IBDs.
COVID-19 alters the local immunity of the lung in ways that weaken the body’s antimicrobial defense and facilitate the development of secondary infections.
The findings of a recent study suggest that phages can be used to treat IBD and other diseases associated with gut microbes.
Ghaith Bakdash described how Microbiotica discovered a specific microbiome signature in patients responder to immune-oncology drugs such as anti-PD1 / PDL1 and developed a new bacterial consortium.
The findings of a recent study suggest that engineered native gut bacteria could be employed to help treat certain diseases such as diabetes.
A recent study suggests that the microbiome changes in response to human consumption of non-nutritive sweetener may induce glycemic changes in consumers in a personalized manner.
Sarah Lebeer (Research professor, University of Antwerp) described how she and her colleagues developed a new probiotic topic formulation to treat Acne.
Antimicrobial resistant bacteria are present in newborns after just a few hours of life and they help to understand the routes of transmission of antibiotic-resistance genes.
The findings of a new research suggest that different responses to statins can be explained by the variation in the human microbiota.
The findings of a new research illuminate the link between IBS and gut bacteria, and suggest that histamine is a good target for therapies against the condition.
The findings of a new research suggest that during the early maturation, the microbiota would be more likely to be influenced by other microbiotas on a not-too-distant level of maturity.
Maria Teresa Abreu (University of Miami, USA) discussed some new strategies to design clinical trials.
Theresa Pizarro, (Case Western Reserve University School of Medicine) discussed the roles of epithelial barrier’s cytokines, gut microbiome and Gasdermin in IBD patients.
